Results
|
|
2021.
|
|
|
|
2022.
|
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. [electronic resource] by
- Blackwell, Kimberly
- Burris, Howard
- Gomez, Patricia
- Lynn Henry, N
- Isakoff, Steven
- Campana, Frank
- Gao, Lei
- Jiang, Jason
- Macé, Sandrine
- Tolaney, Sara M
Producer: 20160909
In:
Breast cancer research and treatment vol. 154
Availability: No items available.
|
|
|
2023.
|
|
|
|
2024.
|
|
|
|
2025.
|
|
|
|
2026.
|
|
|
|
2027.
|
|
|
|
2028.
|
|
|
|
2029.
|
|
|
|
2030.
|
|
|
|
2031.
|
|
|
|
2032.
|
|
|
|
2033.
|
|
|
|
2034.
|
|
|
|
2035.
|
|
|
|
2036.
|
|
|
|
2037.
|
|
|
|
2038.
|
|
|
|
2039.
|
|
|
|
2040.
|
|